Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IDIX
- CUSIP: 45166R20
- Web: N/A
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -28.49
- P/E Growth: 0
Frequently Asked Questions for Idenix Pharmaceuticals (NASDAQ:IDIX)
What is Idenix Pharmaceuticals' stock symbol?
Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."
Who are some of Idenix Pharmaceuticals' key competitors?
Some companies that are related to Idenix Pharmaceuticals include Grifols, S.A. (GRFS), Jazz Pharmaceuticals PLC (JAZZ), ProMetic Life Sciences (PLI), Theratechnologies (TH), Mirati Therapeutics (MRTX), SIGA Technologies (SIGA), Osiris Therapeutics (OSIR), Anavex Life Sciences Corp. (AVXL), VBI Vaccines (VBIV), XOMA Corporation (XOMA), ContraFect Corporation (CFRX), Concordia International Corp (CXR), Protalix Biotherapeutics (PLX), Trillium Therapeutics (TRIL), Aevi Genomic Medicine (GNMX), Ohr Pharmaceuticals (OHRP), Can Fite Biopharma Ltd (CANF) and Can Fite Biopharma Ltd (CANF).
How do I buy Idenix Pharmaceuticals stock?
Shares of Idenix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Idenix Pharmaceuticals' stock price today?
MarketBeat Community Rating for Idenix Pharmaceuticals (NASDAQ IDIX)MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Idenix Pharmaceuticals stock can currently be purchased for approximately $24.50.
Consensus Ratings for Idenix Pharmaceuticals (NASDAQ:IDIX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Idenix Pharmaceuticals (NASDAQ:IDIX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Idenix Pharmaceuticals (NASDAQ:IDIX)Earnings History by Quarter for Idenix Pharmaceuticals (NASDAQ IDIX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/1/2014||Q114||($0.19)||($0.24)||$0.22 million||($3.01) million||View||N/A|
|2/27/2014||Q413||($0.22)||($0.21)||$0.15 million||$0.50 million||View||N/A|
|2/25/2013||Q412||($0.17)||($0.17)||$0.74 million||$0.33 million||View||N/A|
|11/1/2012||Q312||($0.17)||$0.03||$2.60 million||$32.30 million||View||N/A|
Earnings Estimates for Idenix Pharmaceuticals (NASDAQ:IDIX)
Current Year EPS Consensus Estimate: $-0.93 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS
Dividend History for Idenix Pharmaceuticals (NASDAQ:IDIX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Idenix Pharmaceuticals (NASDAQ:IDIX)Insider Trades by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/31/2014||Baupost Group Llc/Ma||major shareholder||Buy||16,420,241||$6.50||$106,731,566.50|| |
Headline Trends for Idenix Pharmaceuticals (NASDAQ:IDIX)
Latest Headlines for Idenix Pharmaceuticals (NASDAQ:IDIX)
Idenix Pharmaceuticals (IDIX) Chart for Monday, September, 25, 2017